Indefinite Delivery Contract 36E79723D0022
Award Date
9/1/23
Last Date to Order
8/31/25
Federal Agency
National Acquisition Center
Awardee
Organon LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) National Acquisition Center has awarded Organon LLC a single-award Indefinite Delivery Contract (IDC) valued at $325,063,436.44 to provide Adalimumab pen and syringe kits. The contract has a base year of March 9, 2024 to March 8, 2025, with four one-year option periods, for a total potential period of performance through March 8, 2026. The IDC will support the VA's Pharmaceutical Prime Vendor program, as well as provide Adalimumab products to the Bureau of...
This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian agency within the U.S. Department of Veterans Affairs (VA), to Pfizer Inc. as the prime contractor. The single-award IDC has a ceiling value of $74,038,216.80 and a base ordering period from September 15, 2025 to September 14, 2026, with four one-year option periods. The contract is for the procurement of Rituximab and its biosimilar products to support multiple federal healthcare agencies,...
The National Acquisition Center, a civilian agency of the U.S. Department of Veterans Affairs, awarded a single-award Indefinite Delivery Contract (IDC) to TG Therapeutics Inc., a for-profit pharmaceutical manufacturer, to provide ublituximab-XIIY 150mg/6ml injection, an anti-CD20 antibody, for a 1-year base period and four 1-year option periods through June 16, 2026. The $186,776,520 IDC was awarded on June 17, 2024 with the intent to list the awarded product as the preferred agent on the VA...
The Department of Veterans Affairs National Acquisition Center awarded Organon LLC a single-award Indefinite Delivery Contract valued at $22,611,464.85 to provide Trastuzumab (ONTRUZANT) 150mg. The contract has a base period plus four one-year option periods, with a total period of performance through November 14, 2025. This IDV will support the VA's Pharmaceutical Prime Vendor program, ensuring a consistent supply of the critical medication for veterans, military personnel, inmates, and...
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a civilian agency of the U.S. federal government, to Pfizer Inc. as the prime contractor. The contract has a total ceiling value of $83,732,812.80 and a period of performance from September 15, 2020 to September 14, 2025, including a base year and four one-year option periods. The purpose of this IDC is to procure rituximab vials for the Department of Veterans Affairs, Department of Defense, Bureau of...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer, for the supply of glatiramer acetate injections. The $64,352,514.80 contract has a base period of one year and four one-year option periods, running from August 2023 to August 2025. This IDC will ensure the delivery of approximately 208,000 syringes of glatiramer acetate 20mg/mL and 40mg/mL...
This federal contract IDV award is for the supply of ranibizumab ophthalmic injections to the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The single-award indefinite delivery contract, valued at $11,392,063.40, was issued by the VA National Acquisition Center to the prime contractor Biogen U.S. Corporation, a for-profit pharmaceutical manufacturer. The contract has a performance period from December 23, 2023, through December 22, 2025, with four...
The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract to Baxter Healthcare Corporation on October 15, 2020, with a potential value of $30,336,036.80. The contract provides for the supply of cyclophosphamide vial injections in 1gm, 2gm, and 500mg sizes to the VA, DOD, BOP and IHS. The pre-solicitation notice indicated annual estimated requirements totaling over 12,000 vials across the three sizes, ranging from over 4,000 to 5,486...
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc. to provide an uninterrupted supply of Bevacizumab (ZIRABEV) for the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The contract has a 1-year base period with four 1-year option periods, for a total potential period of performance through August 12, 2025. The contract value has a ceiling of...
This federal contract IDV award is for the provision of Bevacizumab injections to support multiple federal healthcare organizations, including the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract was awarded to Pfizer Inc. as the single prime contractor, with a ceiling value of $46,893,140.00 and a total ordering period from August 13, 2025 to August 12, 2026, with four additional one-year...